Hypocomplementaemic urticarial vasculitis associated with non-Hodgkin lymphoma and treatment with intravenous immunoglobulin

Shah, D.; Rowbottom, Anthony W.; Thomas, Clayton L.; Cumber, Peter; Chowdhury, M. M. U.

doi:10.1111/j.1365-2133.2007.07983.x

Cited by 29 publications

(19 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Urticarial vasculitis with IgM gammopathy or Schnitzler syndrome has been associated with a higher frequency of hematologic malignant tumors. 4,5 Only limited epidemiologic information is available about the exact extent of the association between chronic urticaria and cancer. Our aim was to evaluate the relative risk of cancer occurrence among chronic urticaria patients who have received longterm antihistamine treatment by means of a nationwide population-based database of Taiwan.…”

mentioning

confidence: 99%

Cancer Risk in Patients With Chronic Urticaria

Chen¹,

Wu²,

Shen

et al. 2012

Arch Dermatol

View full text Add to dashboard Cite

mentioning

confidence: 99%

Cancer Risk in Patients With Chronic Urticaria

Chen¹,

Wu²,

Shen

et al. 2012

Arch Dermatol

View full text Add to dashboard Cite

“…Non‐Hodgkin's lymphoma has also been associated with urticarial vasculitis 10,11 and recalcitrant necrotizing leukocytoclastic vasculitis 12,13 . It has also been reported in association with Sweet's syndrome, which is part of the same spectrum as EED 14 …”

Section: Discussionmentioning

confidence: 99%

Erythema elevatum diutinum with rare distribution as a first clinical sign of non‐Hodgkin's lymphoma: A novel association?

Hatzitolios¹,

Tzellos²,

Savopoulos³

et al. 2008

The Journal of Dermatology

View full text Add to dashboard Cite

We present a case of a 78-year-old man with erythema elevatum diutinum as a first clinical sign of non-Hodgkin's lymphoma. The patient developed erythema elevatum diutinum with an unusual distribution involving the trunk. Erythema elevatum diutinum is a rare dermatosis that is considered to be a localized, low-grade form of leukocytoclastic vasculitis associated with neoplastic, autoimmune and infectious processes. It is probably mediated by immune complexes. Recent studies report hematological disease as the most common factor associated with erythema elevatum diutinum. Many hematological diseases, such as myeloma, myelodysplastic syndrome and immunoglobulin (Ig)A monoclonal gammopathy, have been reported in association with erythema elevatum diutinum, but none with IgM monoclonal gammopathy and only one with malignant lymphoma. We would like to add IgM monoclonal gammopathy and non-Hodgkin's lymphoma as one of the diseases associated with erythema elevatum diutinum considering that the activity of erythema elevatum diutinum and non-Hodgkin's lymphoma fluctuated in parallel in the present case.

show abstract

“…Minimal adverse effects were experienced by the subjects enrolled in this study [63]. In a few instances, IVIG has also been used in some forms of urticarial vasculitis, a complement-mediated inflammatory disorder characterized by leukocytoclasia [65,66].…”

Section: Efficacy Of Ivig In Urticarial Syndromesmentioning

confidence: 97%

Intravenous Immunoglobulin as a Potential Therapy for Refractory Urticaria - A Review

Watkins¹,

Peiris²,

Saleh³

et al. 2012

IADT

View full text Add to dashboard Cite

Urticaria can be a chronic and debilitating affliction and is a relatively common disorder affecting between 10- 20% of the population. Common causes include reactions to medication, food allergen, physical stimuli and venoms. Urticaria can be acute or chronic. Chronic urticaria lasts for more than 6 weeks and is commonly difficult to treat. The use of immunosuppressive agents for this disorder when antihistamines fail can result in significant morbidity. Recent advances in the pathogenesis, etiology, diagnosis and management of chronic urticaria have led to new paradigms in treatment of this disorder. Cyclosporine is often the most effective but has some unique adverse effects that may prevent it from being used in some patients. The use of intravenous immunoglobulin (IVIG) has proven effective in a variety of reports and we will review the mechanisms likely involved in the successful control of urticarial symptoms by immunomodulating therapy using IVIG. In this review, we will discuss mechanisms and pathogenesis of urticaria and the specific role of intravenous immunoglobulin (IVIG) in this disorder, especially in refractory or steroid-dependent cases.

show abstract

Hypocomplementaemic urticarial vasculitis associated with non-Hodgkin lymphoma and treatment with intravenous immunoglobulin

Cited by 29 publications

References 7 publications

Cancer Risk in Patients With Chronic Urticaria

Cancer Risk in Patients With Chronic Urticaria

Erythema elevatum diutinum with rare distribution as a first clinical sign of non‐Hodgkin's lymphoma: A novel association?

Intravenous Immunoglobulin as a Potential Therapy for Refractory Urticaria - A Review

Contact Info

Product

Resources

About